Biochemical Recurrence and Survival Prediction Models for the Management of Clinically Localized Prostate Cancer

Tewari, Ashuthosh; Gamito, Eduard J.; Crawford, E. David; Menon, Mani

doi:10.3816/cgc.2004.n.003

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The natural history of biochemical recurrence after radical prostatectomy can be long but variable. Early identification, before detectable PSA is measured, of men likely to ultimately experience disease progression would be useful in considering early adjuvant therapy [92][93][94][95] . Clinical nomograms predicting freedom from biochemical recurrence 5 and 10 years after RP are in use [31,96] .…”

Section: Tumor Recurrencementioning

confidence: 99%

Incremental value of magnetic resonance imaging in the advanced management of prostate cancer

Wang¹

2009

WJR

View full text Add to dashboard Cite

Prostate cancer is a major public health burden throughout the world. The high incidence of prostate cancer, combined with earlier detection and downstaging at the time of diagnosis, and the slow natural progression and biological heterogeneity of the disease, has made its management a complex and controversial issue. There is growing demand for patient-specific therapies that can minimize treatment morbidity while maximizing treatment benefits. There are a number of clinical parameters and clinical nomograms to help with the choice of treatment. Magnetic resonance imaging (MRI) is a technique which makes safer, more individualized therapies possible due to high spatial resolution, superior contrast resolution, multiplanar capability, and a large field of view. Other MRI techniques such as MR spectroscopic imaging, dynamic contrast-enhanced MRI or perfusion MRI, and diffusion-weighted imaging complement MRI by reflecting tissue biochemistry, Brownian motion of water molecules, and capillary wall permeability, respectively. This editorial review highlights the incremental value of MRI in the advanced management of prostate cancer to non-invasively improve cancer staging, biologic potential, treatment planning, therapy response, local recurrence, and to guide target biopsy for clinical suspected cancer with previous negative biopsy. Finally, some future prospects for MRI in prostate cancer management are given.

show abstract